Dengue fever remains one of the most significant tropical diseases, particularly in countries with tropical climates such as Indonesia. This disease is transmitted through the bite of Aedes aegypti mosquitoes carrying the dengue virus. To this day, dengue fever continues to cause high rates of illness and hospitalization, and in some cases may progress to severe, life-threatening complications. Therefore, preventive measures play a crucial role, one of which is vaccination.
The Qdenga vaccine is a vaccine that helps protect the body against dengue fever. The Qdenga vaccine can be administered to adults, adolescents, and children starting from the age of 6 years. In most cases, dengue infection initially causes mild symptoms. However, in a small proportion of patients, the disease can progress to a more severe condition characterized by bleeding, plasma leakage, and organ damage that may be fatal. This is why prevention through vaccination is an essential step in reducing the risk of severe dengue.
Symptoms of dengue fever usually appear suddenly and may vary among individuals. The most common symptom is a high fever accompanied by one or more of the following:
Dengue symptoms typically last for 2–7 days. Most patients recover within about one week. However, during certain phases, the disease may worsen and lead to bleeding or dengue shock syndrome, which requires immediate medical attention. Given the potential severity of these complications, preventive measures are essential to reduce risk.
Because the symptoms and complications of dengue fever can be serious, vaccination with the Qdenga vaccine can help reduce the risk of disease progression. The Qdenga vaccine is designed to provide protection against all four known dengue virus types. With protection against all dengue serotypes, the risk of severe infection and hospitalization due to dengue can be significantly reduced.
The Qdenga vaccine is a dengue fever vaccine that provides protection against the four dengue virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. The Qdenga vaccine uses a live attenuated dengue virus, which stimulates the immune system to develop a protective response without causing disease.
The Qdenga vaccine is administered via subcutaneous injection (under the skin). The Qdenga vaccine is intended for individuals aged 6 to 45 years and is given in two doses with a specific interval. The two-dose schedule aims to build and strengthen immunity against the dengue virus optimally.
The Qdenga vaccine contains all four attenuated dengue virus serotypes. These components train the immune system to recognize and fight each type of dengue virus. As a result, if an individual who has received the Qdenga vaccine is exposed to the dengue virus in the future, the body already has better defenses to prevent severe infection.
The Qdenga vaccine is administered subcutaneously in a two-dose schedule. The first dose is given on day 0, followed by a second dose three months later. Adhering to this schedule is important to ensure optimal protection. The Qdenga vaccine is recommended for individuals aged 6 to 45 years, with the goal of reducing the risk of severe complications from dengue infection in this age group.
The Qdenga vaccine has been developed to help prevent the progression of dengue fever to more severe forms. The Qdenga vaccine has demonstrated a good level of protection, particularly in reducing the risk of severe dengue cases and the need for hospitalization. The efficacy of the Qdenga vaccine may vary depending on the age of the recipient and the duration of observation after vaccination.
In terms of safety, the Qdenga vaccine is generally well tolerated. Reported side effects are usually mild and temporary, such as pain at the injection site or mild fever. However, there are certain contraindications to the Qdenga vaccine, including individuals with congenital or acquired immunodeficiency due to medical conditions, patients receiving immunosuppressive therapy such as chemotherapy or high-dose systemic corticosteroids within four weeks prior to vaccination, individuals with HIV infection accompanied by impaired immune function, as well as pregnant and breastfeeding women.
Some side effects that may occur after administration of the Qdenga vaccine include temporary fever, pain or redness at the injection site, and headache. These side effects are generally mild and resolve on their own within a short period of time.
The Qdenga vaccine is an effective preventive measure to help protect against dengue fever, particularly in reducing the risk of severe infection, bleeding complications, and hospitalization. With protection against all four dengue virus serotypes and a proven two-dose vaccination schedule, the Qdenga vaccine is an important option for maintaining long-term health, especially for children, adolescents, and adults aged 6 to 45 years living in dengue-endemic areas.
Vaccination not only protects individuals but also contributes to reducing the overall burden of disease in the community. Therefore, the public is encouraged not to delay vaccination and to consult trusted healthcare professionals regarding the Qdenga vaccine.
To receive the Qdenga vaccine safely and according to medical standards, you may visit the nearest Nusa Medica Clinic. With professional services and experienced medical staff, Nusa Medica Clinic is ready to assist you and your family in obtaining optimal protection against dengue fever.
✨ Protect yourself and your loved ones starting today — get vaccinated with the Qdenga vaccine at your nearest Nusa Medica Clinic.
References
Writer: dr. Ni Putu Nadya Agustine Anandito - General Practitioner & Chief Medical Officer Nusa Medica Clinic Canggu
